Retinal photo tool to predict heart risk in new heart failure patients
Tests a retinal photo risk score in adults newly diagnosed with reduced-ejection heart failure.
Key facts
- Who runs it
- Yonsei University
- Where
- Seoul, South KoreaSee the site
- Trial code
- Registry title
- Validation of the Prognostic Impact of a Retinal Photograph-based Cardiovascular Disease Risk Stratification System in de Novo HFrEF
- Status
- Recruiting
- People taking part
- 100 people, planned
- Started
- 10 Dec 2024
- Expected to end
- 10 Dec 2030
- Type of study
- Observational
- Record updated
- 18 May 2025
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults aged 20 to 79 with newly diagnosed heart failure and a weak heart pump (ejection fraction of 40% or less). It tests whether a photograph of the back of the eye can predict outcomes.
- Age
- 20 to 79 years
- Sex
- All sexes can join.
- Disease stage
- Left ventricular ejection fraction of 40% or less, measured by an ultrasound of the heart (transthoracic echocardiography). The title says newly diagnosed heart failure.
Main reasons for not taking part
- Severe eye disease that prevents good-quality photos of the back of the eye
- Extensive retinal disease that makes the retinal blood vessels hard to see
- Pregnant individuals
- People who cannot decide for themselves whether to take part
- People who decline to give informed consent
The registry criteria, word for word
Show all 6 criteriaShow less
Who can take part
- Patients aged between 20 and 79 years with a left ventricular ejection fraction of 40% or less (assessed by transthoracic echocardiography), who have provided written consent for participation, have the capability to consent voluntarily
Who cannot take part
- Inability to obtain high-quality fundus photographs due to severe ophthalmologic conditions
- Presence of extensive retinal diseases that significantly impair visualization of the retinal vasculature
- Decline to provide informed consent for study participation, including:
- Pregnant individuals
- Individuals lacking decision-making capacity
Where in South Korea
- Severance hospitalSeoul, South KoreaContact: Chan Joo LeeTaking people
About the trial
What the trial wants to find out
"Despite significant advances in pharmacologic and device-based therapies, heart failure (HF) remains a major public health burden, with persistently high rates of hospitalization, impaired quality of life, and excess mortality-often exceeding those of leading malignancies. Prognosis in HF is shaped by its underlying etiology: ischemic HF often responds to revascularization strategies, whereas non-ischemic HF, particularly due to idiopathic or genetic cardiomyopathies, demonstrates highly variable outcomes and limited responsiveness to guideline-directed medical therapy (GDMT). Although left ventricular reverse remodeling (LVRR) is associated with favorable outcomes, only 40-50% of non-ischemic HF patients achieve meaningful LVRR with GDMT alone.
Read full original descriptionShow less
In this context of therapeutic uncertainty and prognostic heterogeneity, there is a critical need for novel, non-invasive risk stratification tools. Retinal imaging offers a unique advantage, enabling direct, in vivo visualization of systemic microvascular and neurovascular integrity. Prior work from our group has demonstrated that deep learning algorithms applied to retinal fundus photographs can estimate physiologic and metabolic markers-including CAC scores-and predict future cardiovascular events. The Reti-CVD scoring system, derived from these models, has been externally validated in independent populations.
In the present study, we aim to evaluate the prognostic utility of the Reti-CVD model in a cohort of patients with newly diagnosed HF and reduced ejection fraction. Specifically, we will assess whether retinal-derived risk scores at baseline are associated with adverse clinical outcomes, including cardiovascular events and all-cause mortality, and whether prognostic performance varies according to HF etiology."
The group in the trial
- De novo Heart Failure cohort
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- Validation of the Prognostic Impact of a Retinal Photograph-based Cardiovascular Disease Risk Stratification System in de Novo HFrEF
- Plain-language title
- Retinal photo tool to predict heart risk in new heart failure patientsGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 12 November 2026.
- Record updated
- 18 May 2025